Previously we found that uroguanylin displayed a specific expression pattern in the uteri during pregnancy. In this study, the effect of uroguanylin in early pregnancy was studied by DNA vaccine, RT-PCR, Western blot, immunofluorescence and immunohistochemistry. The results showed that (1) the anti-rUfl antibodies could be elicited in the mice after immunization by recombinant plasmid pCR3.1-rUfl; (2) the birth rate of the female mice immunized by pCR3.1-rUfl was significantly reduced (p<0.01); (3) anti-rUfl antibodies could bind with uroguanylin in the uteri of the non-pregnant mice immunized by pCR3.1-rUfl; (4) in the non-mated experiments, in the uteri of normal, pCR3.1- and pCR3.1-rUfl-immunized mice, expression of p53 and vascular endothelial growth factor (VEGF) was not detected, Bax was expressed, and transforming growth factor beta 1 (TGFbeta1) expression was very little; (5) in the mated experiments, p53, Bax, VEGF and TGFbeta1 were expressed in the uteri of saline- and pCR3.1-immunized mice that were pregnant. However, their expression was significantly decreased in the uteri of the non-pregnant mice immunized by pCR3.1-rUfl on the 9th day of pregnancy (p<0.01). The results indicate that the immunization by pCR3.1-rUfl has antifertility effect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2008.04.086 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!